[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholecystectomy-robotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholecystectomy-robotic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641076","opiranserin-for-minimally-invasive-cholecystectomy-100641076",false,"NCT07620665","Opiranserin for Minimally Invasive Cholecystectomy","Comparison of Opiranserin\u002FAcetaminophen Versus Ibuprofen\u002FAcetaminophen for Postoperative Pain Management After Minimally Invasive Cholecystectomy: A Randomized, Controlled, Non-inferiority Trial","Inclusion Criteria:\n\n* Adult patient undergoing minimally invasive cholecystectomy\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to acetaminophen, NSAIDs, opiranserin, or fentanyl.\n* pre-existing chronic pain,\n* clinically significant ECG findings (QRS \\> 200 msec, QTcF \\>450 msec)\n* severe renal impairment\n* severe hepatic impairment","ALL","19 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate whether the combination therapy of opiranserin and acetaminophen is non-inferior to the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for postoperative pain management after minimally invasive cholecystectomy.\n\nThis is a single-center, randomized, controlled, non-inferiority clinical trial in adult patients undergoing minimally invasive cholecystectomy. Participants will be randomly assigned to either the Treatement group (opiranserin + acetaminophen) or the control group (NSAIDs + acetaminophen) in a 1:1 ratio to compare the analgesic efficacy and safety between the two analgesic regimens.",[26,27],"Cholecystectomy, Laparoscopic","Cholecystectomy, Robotic","RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":32},"2026-06-10",{"date":36,"type":20},"2028-05-30",{"name":38,"class":39},"Gangnam Severance Hospital","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100602107","surgical-techniques-robotic-versus-conventional-laparoscopic-cholecystectomy-in-benign-gallbladder-disease-100602107","NCT07119203","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease: A Randomized Controlled, Open, Parallel, Non-inferiority, Single-center Trial (STaRLING Trial)","STaRLING","Inclusion Criteria:\n\n* Age equal or above 18 years;\n* Benign gallbladder disease: diagnosis of gallbladder polyps or symptomatic gallstones proven on imaging (ultrasound, computed tomography (CT) scan or magnetic resonance cholangiopancreatography (MRCP));\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\n* Minimally invasive procedure is not deemed possible by the operating surgeon;\n* Evidence of acute cholecystitis;\n* Known stones in the common bile duct (CBD);\n* Suspicion of possible malignancy;\n* Pregnancy;\n* Diagnosis of liver cirrhosis (stage III or IV);\n* Insufficient language skills to be able to perform the quality-of-life questionnaires.","18 Years",{"count":51,"type":20},276,[23],"This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively.\n\nThis is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.",[27,26,55,56,57],"Cholecystectomy","Gallstones","Benign Gallbladder Disease",[59,60,61,62,63],"Robotic cholecystectomy","Laparoscopic cholecystectomy","Benign gallbladder disease","Randomized controlled trial","Cost-effectiveness","2025-12-16",{"date":66,"type":32},"2025-12-23",{"date":68,"type":32},"2025-09-12",{"date":70,"type":20},"2026-06-01",{"name":72,"class":73},"Portsmouth Hospitals NHS Trust","OTHER_GOV",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100600389","post-market-clinical-study-to-evaluate-the-performance-of-the-versius-surgical-system-100600389","NCT07096856","Post Market Clinical Study to Evaluate the Performance of the Versius Surgical System","Inclusion Criteria:\n\n* 1\\. Adult patients 22 years of age and older, eligible for soft tissue minimal access surgery, for cholecystectomy 2. Patients providing written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Patient unwilling to provide informed consent\n2. Patients undergoing surgery or treatment for malignant disease\n3. Patients undergoing a concomitant surgical procedure\n4. Medical contraindication for general anaesthesia or minimally invasive procedure\n5. Contraindication for undergoing surgery with Versius (Bleeding diathesis, Active pregnancy or BMI ≥40 kg\u002Fm2)","22 Years",{"count":83,"type":20},100,[23],"The goal of this clinical trial is to learn how the Versius Surgical System, a robotic surgery device, works for gallbladder removal surgery (cholecystectomy) in adults. The main questions it aims to answer are:\n\nHow often can the surgery be successfully completed using Versius without needing to switch to a different surgical method?\n\nWhat serious complications, if any, occur within 30 days after surgery?\n\nResearchers will collect information from adult patients who have gallbladder surgery using the Versius system in U.S. hospitals. The purpose is to better understand how the device performs and how patients recover after surgery.\n\nParticipants will:\n\nBe adults age 22 or older who are eligible for minimally invasive gallbladder surgery\n\nUndergo robotic-assisted surgery using the Versius Surgical System\n\nAllow the research team to collect data during surgery and up to 30 days after\n\nComplete standard follow-up visits after discharge\n\nPatients with certain medical conditions, such as cancer, high BMI (≥40 kg\u002Fm²), or contraindications to anesthesia or robotic surgery, will not be included in the study.\n\nThis study is sponsored by CMR Surgical Ltd., the manufacturer of the Versius system.",[27],"NOT_YET_RECRUITING","2025-07-24",{"date":90,"type":32},"2025-07-31",{"date":92,"type":20},"2025-12",{"date":94,"type":20},"2026-03",{"name":96,"class":97},"CMR Surgical Ltd","INDUSTRY"]